Skyrizi

What Skyrizi is used for

Adult plaque psoriasis Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Paediatric plaque psoriasis Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. Psoriatic Arthritis Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Crohn’s disease Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. Ulcerative colitis Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Skyrizi

Active substance

risankizumab

Disease area

Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease

Medicine group

Immunosuppressants

ATC code

L04AC18

Marketing authorisation holder

AbbVie Deutschland GmbH & Co. KG

Authorised in the EU since

2019

Official information

• Skyrizi: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Skyrizi